AQX-1125
Phase 3Small molecule
AQX-1125 is one of 81 small molecule programs targeting Chronic Prostatitis. It is currently in Phase 3.
3
Indications
7
Total Trials
0
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Nereus
VVanda Pharmaceuticals
Phase 3
Celestone
SSchering-Plough
Phase 3
Tagamet
DDT MedTech, LLC
Phase 3
Bepreve
BBausch Health Americas, Inc.
Phase 3
AQX-1125
AAquinox Pharmaceuticals (Canada) Inc.
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Prograf
VVeloxis Pharmaceuticals
Preclinical
IDP-124 Lotion
BBausch Health Americas, Inc.
Phase 3
Adtralza
LEO PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Interstitial Cystitis1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AQX-1125. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details